Form 8-K - Current report:
SEC Accession No. 0001193125-26-129170
Filing Date
2026-03-27
Accepted
2026-03-27 16:30:42
Documents
12
Period of Report
2026-03-25
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d122194d8k.htm   iXBRL 8-K 26158
2 EX-3.1 d122194dex31.htm EX-3.1 3756
  Complete submission text file 0001193125-26-129170.txt   148908

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA kymr-20260325.xsd EX-101.SCH 2851
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE kymr-20260325_lab.xml EX-101.LAB 18737
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kymr-20260325_pre.xml EX-101.PRE 11707
15 EXTRACTED XBRL INSTANCE DOCUMENT d122194d8k_htm.xml XML 3853
Mailing Address 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472
Business Address 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472 857-285-5314
Kymera Therapeutics, Inc. (Filer) CIK: 0001815442 (see all company filings)

EIN.: 812992166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39460 | Film No.: 26807888
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)